Search International and National Patent Collections

1. (WO2017191147) COMBINATION THERAPY WITH CPG TLR9 LIGAND

Pub. No.:    WO/2017/191147    International Application No.:    PCT/EP2017/060444
Publication Date: Fri Nov 10 00:59:59 CET 2017 International Filing Date: Thu May 04 01:59:59 CEST 2017
IPC: A61K 39/00
A61K 39/12
A61K 39/39
Applicants: TRANSGENE SA
OLIGOVAX
Inventors: RITTNER, Karola
KRATZER, Roland
CARPENTIER, Antoine
Title: COMBINATION THERAPY WITH CPG TLR9 LIGAND
Abstract:
The present invention generally relates to an immunostimulatory combination comprising a first composition comprising a therapeutic vaccine and a second composition comprising one or more TLR9 ligand(s) such as CpG-containing oligonucleotide(s) as well as the use of such a first composition in combination with said second composition for treating a subject in need thereof. A specific embodiment is directed to the combination of a vectorized therapeutic vaccine encoding antigen(s) and a CpG-containing oligonucleotide such as Litenimod. Embodiments also include kits comprising such compositions as well as methods for treating, preventing or inhibiting diseases, in particular proliferative diseases or infectious diseases comprising administration of such first and second compositions. The invention is of very special interest in the field of immunotherapy, specifically for enhancing host's innate immune response, modifying local cytokine and chemokine profile and leukocyte populations at or around the treatment site and/or at or around the site of infection.